Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2261 to 2270 of 2579 total matches.

Pergolide And Selegiline For Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 08, 1989  (Issue 800)
tablet each day, and then increasing the dosage over the next 12 days by 0.1 or 0.15 mg every third day ...
Levodopa combined with carbidopa (Sinemet) is the treatment of choice for Parkinson's disease (Medical Letter, 30:113, 1988). After prolonged treatment, however, the symptoms of the disease often become difficult to manage. The benefit from each dose becomes shorter (the 'wearing-off' effect), sudden fluctuations occur between mobility and immobility (the 'on-off' phenomenon), and abnormal involuntary movements (dyskinesias) may become frequent. The dopamine agonist bromocriptine (Parlodel) can ameliorate some of these effects. Two new drugs, pergolide (Permax - Lilly), another dopamine...
Med Lett Drugs Ther. 1989 Sep 8;31(800):81-3 |  Show IntroductionHide Introduction

New Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998  (Issue 1040)
%) with placebo. Mean Sharp X-ray scores were -0.06 for leflunomide, +1.4 for sulfasalazine and +5.6 for placebo ...
Leflunomide (Arava - Hoechst Marion Roussel), which inhibits pyrimidine synthesis, and etanercept (Enbrel - Immunex/Wyeth-Ayerst), which blocks the action of tumor necrosis factor (TNF), have been approved by the FDA for treatment of rheumatoid arthritis. A third drug, infliximab (Remicade - Centocor), which also blocks TNF and has been used to treat rheumatoid arthritis, was approved earlier for treatment of Crohn's disease. Its use in Crohn's disease will be reviewed in a future issue.
Med Lett Drugs Ther. 1998 Nov 20;40(1040):110-2 |  Show IntroductionHide Introduction

FluMist: An Intranasal Live Influenza Vaccine

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2003  (Issue 1163)
was 93% effective in preventing culture-proven influenza in year 1 and 87% effective in year 2 (RB ...
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray, it stimulates immunity by viral replication in the upper respiratory tract. This vaccine apparently will be advertised directly to the public as a "needle-free" alternative to intramuscular influenza vaccine.
Med Lett Drugs Ther. 2003 Aug 19;45(1163):65-6 |  Show IntroductionHide Introduction

Vytorin: A Combination of Ezetimibe and Simvastatin

   
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004  (Issue 1191)
20 mg 137.87 40 mg 137.87 80 mg 137.87 *Cost of 30 days’ treatment with 1 tablet/day, according ...
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe (Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin (Zocor - Merck), has been approved by the FDA for treatment of hypercholesterolemia. It is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40 or 80 mg of simvastatin.
Med Lett Drugs Ther. 2004 Sep 13;46(1191):73-4 |  Show IntroductionHide Introduction

In Brief: Testing for Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007  (Issue 1264)
physical examination and exploratory surgery, 2 tests are commonly used. 1 Transvaginal ultrasound (TVUS ...
Recent publicity about symptoms of ovarian cancer will prompt many questions from patients about testing for the disease. Early-stage epithelial ovarian cancer is potentially curable, with survival rates of 90-95%, but about 75% of women have advanced or metastatic disease at diagnosis. Between physical examination and exploratory surgery, 2 tests are commonly used.1Transvaginal ultrasound (TVUS) images the ovaries better than transabdominal ultrasound. In a study in which 25,327 asymptomatic women were screened with TVUS annually from 1987 to 2005, 364 patients had exploratory surgery, and 44...
Med Lett Drugs Ther. 2007 Jul 2;49(1264):53 |  Show IntroductionHide Introduction

Extended-Release Fluvoxamine (Luvox CR)

   
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008  (Issue 1289)
), a tricyclic antidepressant/serotonin reuptake inhibitor. 1 The immediate-release form of fluvoxamine ...
Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI) that has been available for many years in an immediate-release formulation (Luvox, and others) for treatment of obsessive-compulsive disorder (OCD) in children and adults, has now been approved by the FDA in an extended-release formulation (Luvox CR - Jazz Pharmaceuticals) for treatment of OCD and social anxiety disorder (SAD) in adults.
Med Lett Drugs Ther. 2008 Jun 30;50(1289):50-1 |  Show IntroductionHide Introduction

Prostate Cancer Screening

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008  (Issue 1298)
against screening men >75 years old. 1 The median age of death from prostate cancer is 80 ...
The US Preventive Services Task Force (USPSTF) has recently concluded that available evidence is insufficient to assess the balance between potential benefits and harms of using the prostate-specific antigen (PSA) to screen men < 75 years old for prostate cancer and has recommended against screening men > 75 years old.
Med Lett Drugs Ther. 2008 Nov 3;50(1298):85-6 |  Show IntroductionHide Introduction

Red Yeast Rice

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009  (Issue 1320)
by weight from 0% to 0.58%. 1 In another, among 10 such products, monacolin K content varied 100-fold. 2 ...
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Med Lett Drugs Ther. 2009 Sep 7;51(1320):71-2 |  Show IntroductionHide Introduction

Plerixafor (Mozobil)

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2010  (Issue 1335)
with G-CSF alone. 1 MECHANISM OF ACTION — Plerixafor is a small-molecule bicyclam derivative ...
The FDA has approved plerixafor (Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen) to mobilize peripheral blood stem cells in adults with multiple myeloma or non-Hodgkin’s lymphoma before high-dose chemotherapy with autologous stem cell rescue.
Med Lett Drugs Ther. 2010 Apr 5;52(1335):27-8 |  Show IntroductionHide Introduction

Posaconazole (Noxafil) for Invasive Fungal Infections

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 2006  (Issue 1248)
of other fungal infections, including those caused by Mucor and other Zygomycetes. 1 of candidiasis ...
Posaconazole (Noxafil - Schering-Plough), an oral azole antifungal with a chemical structure similar to that of itraconazole (Sporanox), has been approved by the FDA to prevent Candida and Aspergillus infections in severely immunocompromised patients and for treatment of oropharyngeal candidiasis. It is likely also to be used off-label for treatment of other fungal infections, including those caused by Mucor and other Zygomycetes.
Med Lett Drugs Ther. 2006 Nov 20;48(1248):93-5 |  Show IntroductionHide Introduction